References
- Abdul Rani R, Raja Ali RA, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res. 2016;14(4):297–304.
- Weimers P, Burisch J. The Importance of Detecting Irritable Bowel-like Symptoms in Inflammatory Bowel Disease Patients. J Crohns Colitis. 2018;12(4):385–386.
- Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108–2131.
- Jones R, Hunt C, Stevens R, et al. Management of common gastrointestinal disorders: quality criteria based on patients’ views and practice guidelines. Br J Gen Pract. 2009;59(563):415–421.
- National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. DG11.: NICE. 2013. Available from: https://www.nice.org.uk/guidance/dg11/resources/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel-pdf-1053624751045
- Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:55.
- Mendall MA, Chan D, Patel R, et al. Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn’s Disease. BMC Gastroenterol. 2016;16(1):126.
- Turvill J, Turnock D, Holmes H, et al. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterol. 2018;9(4):285.
- Turvill J. The York Faecal Calprotectin Care Pathway for use in primary care. 2018. Available from: http://www.ahsn-nenc.org.uk/wp-content/uploads/2018/06/James-Turvill.pdf
- Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123(2):450–460.
- National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. NICE; 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care 2018. Kent Uo. 2018.
- National Institute for Health and Care Excellence (NICE). BNF. NICE. 2019. Available from: https://bnf.nice.org.uk/
- Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18(12):2301–2309.
- Ananthakrishnan AN, Khalili H, Pan A, et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: results from the Nurses’ Health Study. Clin Gastroenterol Hepatol. 2013;11(1):57–62.
- Loftus EV Jr., Guerin A, Yu AP, et al. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am J Gastroenterol. 2011;106(9):1670–1677.
- Ranjbaran Z, Keefer L, Farhadi A, et al. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22(11):1748–1753.
- Nahon S, Lahmek P, Paupard T, et al. Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn’s Disease Patients. Dig Dis Sci. 2016;61(11):3278–3284.
- Nguyen VQ, Jiang DF, Hoffman SN, et al. Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a US Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2017;23(10):1825–1831.
- Schoepfer AM, Dehlavi MA, Fournier N, et al. Diagnostic Delay in Crohn’s Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. Am J Gastroenterol. 2013;108(11):1744–1753.